Please assess the completion status of the following clinical trial:

Trial Title: The DAWN Antivirals Trial for Ambulatory COVID-19 Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 40 years or older;~* At least 2 Covid-19 suggestive symptoms at the time of inclusion, with onset of a maximum of 5 days prior to enrolment, and which cannot be explained by an alternative cause, and defined by the current Sciensano case definition~* Positive result on PCR test or rapid Ag test in the 7 days before inclusion or at the time of inclusion;~* Patient is community dwelling;~* Participant or their proxy is willing and able to give informed consent for participation in the trial;~* Participant is willing to comply with all trial procedures.~Exclusion Criteria:~* Hospital admission is required at the time of possible recruitment;~* Positive PCR or rapid antigen test for SARS-CoV-2 in the last 2 months other than a test at recruitment or in the 7 days prior to recruitment;~* Participating in any other interventional drug clinical study before enrolment in the study;~* Breastfeeding;~* Known severe neurological disorder, especially seizures in the last 12 months;~* Known allergy to camostat or molnupiravir;~* Previous adverse reaction to, or currently taking, camostat or molnupiravir;~* Patients in palliative care;~* Pregnant women or women of childbearing potential who may become pregnant during the trial and don't agree to use any of the effective contraceptive measures lised above;~* Judgement of the recruiting clinician deems participant ineligible.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Camostat (Type: EXPERIMENTAL): 4 x 200 milligram per day for 7 days
- Placebo (Type: PLACEBO_COMPARATOR): 4 x per day for 7 days
- Molnupiravir (Type: EXPERIMENTAL): 2 x 800 milligram per day for 5 days

Based on this trial design, predict the completion outcome and termination type (if applicable).